Similar articles for PMID: 22294576

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
1912	1
1939	1
1947	1
1949	1
1951	2
1952	1
1972	2
1975	1
1983	2
1987	1
1988	2
1989	3
1990	2
1991	5
1992	5
1993	4
1994	1
1995	7
1996	13
1997	6
1998	10
1999	4
2000	3
2001	5
2002	8
2003	3
2004	1
2005	5
2006	3
2007	3
2008	2
2009	1
2010	14
2011	40
2012	6
2013	2
2014	17
2015	6
2016	6
2017	4
2018	15
2019	7
2020	11
2021	12
2022	7

Results by year

Page 1

Evolution of approaches to viral safety issues for biological products.

Lubiniecki AS. Lubiniecki AS. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):547-56. doi: 10.5731/pdajpst.2011.00818. PDA J Pharm Sci Technol. 2011. PMID: 22294576

Current testing methods and challenges for detection of adventitious viruses.

Khan AS. Khan AS. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):627-33. doi: 10.5731/pdajpst.2011.00831. PDA J Pharm Sci Technol. 2011. PMID: 22294589

Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.

Rosenberg AS, Cherney B, Brorson K, Clouse K, Kozlowski S, Hughes P, Friedman R. Rosenberg AS, et al. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):563-7. doi: 10.5731/pdajpst.2011.00820. PDA J Pharm Sci Technol. 2011. PMID: 22294578

Regulatory approaches for control of viral contamination of vaccines.

McClenahan S, Uhlenhaut C, Krause PR. McClenahan S, et al. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):557-62. doi: 10.5731/pdajpst.2011.00819. PDA J Pharm Sci Technol. 2011. PMID: 22294577

Practicing safe cell culture: applied process designs for minimizing virus contamination risk.

Kiss RD. Kiss RD. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):715-29. doi: 10.5731/pdajpst.2011.00852. PDA J Pharm Sci Technol. 2011. PMID: 22294606

Identification and remediation of a cell culture virus contamination.

Jones N. Jones N. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):615. doi: 10.5731/pdajpst.2011.00822. PDA J Pharm Sci Technol. 2011. PMID: 22294585

Theory and practice of conventional adventitious virus testing.

Gregersen JP. Gregersen JP. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):634-44. doi: 10.5731/pdajpst.2011.00832. PDA J Pharm Sci Technol. 2011. PMID: 22294590

A biotech production facility contamination case study--minute mouse virus.

Skrine J. Skrine J. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):599-611. doi: 10.5731/pdajpst.2011.00823. PDA J Pharm Sci Technol. 2011. PMID: 22294582

Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections.

Eltermann J. Eltermann J. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):694-7. doi: 10.5731/pdajpst.2011.00845. PDA J Pharm Sci Technol. 2011. PMID: 22294603

FDA post-approval expectations for adventitious virus contamination prevention.

Friedman RL. Friedman RL. PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):698-712. doi: 10.5731/pdajpst.2011.00846. PDA J Pharm Sci Technol. 2011. PMID: 22294604

241 results

Page of 25

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed